RU2009102512A - Терапевтические соединения - Google Patents

Терапевтические соединения Download PDF

Info

Publication number
RU2009102512A
RU2009102512A RU2009102512/04A RU2009102512A RU2009102512A RU 2009102512 A RU2009102512 A RU 2009102512A RU 2009102512/04 A RU2009102512/04 A RU 2009102512/04A RU 2009102512 A RU2009102512 A RU 2009102512A RU 2009102512 A RU2009102512 A RU 2009102512A
Authority
RU
Russia
Prior art keywords
pain
disease
caused
cancer
inflammation
Prior art date
Application number
RU2009102512/04A
Other languages
English (en)
Russian (ru)
Inventor
Эдвард Дэниел СЕЙВОРИ (GB)
Эдвард Дэниел СЕЙВОРИ
Original Assignee
Биовитрум Аб (Пабл) (Se)
Биовитрум Аб (Пабл)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биовитрум Аб (Пабл) (Se), Биовитрум Аб (Пабл) filed Critical Биовитрум Аб (Пабл) (Se)
Publication of RU2009102512A publication Critical patent/RU2009102512A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
RU2009102512/04A 2006-06-27 2007-06-26 Терапевтические соединения RU2009102512A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0601396 2006-06-27
SE0601396-5 2006-06-27
US83730806P 2006-08-11 2006-08-11
US60/837,308 2006-08-11

Publications (1)

Publication Number Publication Date
RU2009102512A true RU2009102512A (ru) 2010-08-10

Family

ID=38545430

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009102512/04A RU2009102512A (ru) 2006-06-27 2007-06-26 Терапевтические соединения

Country Status (12)

Country Link
US (1) US7906518B2 (https=)
EP (1) EP2066685B1 (https=)
JP (1) JP2009541436A (https=)
CN (1) CN101479290A (https=)
AT (1) ATE500263T1 (https=)
AU (1) AU2007263726A1 (https=)
BR (1) BRPI0713901A2 (https=)
CA (1) CA2657973A1 (https=)
DE (1) DE602007012904D1 (https=)
ES (1) ES2361886T3 (https=)
RU (1) RU2009102512A (https=)
WO (1) WO2008000743A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2274007B1 (en) * 2008-03-10 2016-12-14 Cornell University Modulation of blood brain barrier permeability
US20100160250A1 (en) * 2008-12-18 2010-06-24 Douglass Iii James G Method for treating inflammatory conditions
RU2478392C2 (ru) * 2011-05-20 2013-04-10 Евгений Петрович Измайлов Способ консервативного и физиотерапевтического лечения серозно-геморрагического плеврита
RU2478391C2 (ru) * 2011-05-20 2013-04-10 Евгений Петрович Измайлов Способ физиотерапевтического и консервативного лечения плеврита
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
MX367879B (es) * 2012-08-01 2019-09-10 Lewis And Clark Pharmaceuticals Inc N-alquil 2-(disustituido)alquiladenosin-5-uronamidas como agonistas a2a.
US11541071B1 (en) * 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5691188A (en) * 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
CN1292073C (zh) 1997-06-03 2006-12-27 森庸厚 天然抗肿瘤性或抗病毒性物质及其用途
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
EP1255550A2 (en) * 2000-02-17 2002-11-13 Cv Therapeutics, Inc. Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
US20090068101A9 (en) * 2003-06-09 2009-03-12 Endacea, Inc. A1 Adenosine Receptor Antagonists
EP1646390B1 (en) * 2003-07-22 2008-10-08 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
BRPI0412577A (pt) * 2003-07-31 2006-09-19 Sanofi Aventis derivados de aminoquinolina e seu uso como ligantes de adenosina a3
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
JP2007514647A (ja) * 2003-10-21 2007-06-07 インスパイアー ファーマシューティカルズ，インコーポレイティド テトラヒドロ−フロ［３，４−ｄ］ジオキソール化合物並びに血小板凝集を阻害する組成物及び方法
JP2007509180A (ja) * 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
WO2006033709A2 (en) * 2004-07-29 2006-03-30 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
US20080221060A1 (en) 2004-03-05 2008-09-11 Martyn Pritchard Therapeutic Compounds
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
US7396825B2 (en) * 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
JP2008512457A (ja) * 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
WO2006113615A2 (en) * 2005-04-15 2006-10-26 Sloan-Kettering Institute For Cancer Research Anti-microbial agents and uses thereof
US7514417B2 (en) * 2005-05-19 2009-04-07 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP1983990B1 (en) * 2006-01-26 2011-03-23 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services A3 adenosine receptor allosteric modulators
WO2007092936A2 (en) * 2006-02-08 2007-08-16 University Of Virginia Patent Foundation Method to treat gastric lesions
CA2644996A1 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2007109547A2 (en) * 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
US20080312160A1 (en) * 2007-04-09 2008-12-18 Guerrant Richard L Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) * 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
US8153781B2 (en) * 2007-06-29 2012-04-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
WO2009052310A1 (en) * 2007-10-16 2009-04-23 Cv Therapeutics, Inc A3 adenosine receptor antagonists
WO2009061516A1 (en) * 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
CN101938904A (zh) * 2008-01-09 2011-01-05 PGx健康有限责任公司 用a2ar激动剂鞘内治疗神经性疼痛
US20090203689A1 (en) * 2008-02-07 2009-08-13 Arvinder Dhalla Abca-1 elevating compounds and methods

Also Published As

Publication number Publication date
JP2009541436A (ja) 2009-11-26
US20080027081A1 (en) 2008-01-31
US7906518B2 (en) 2011-03-15
BRPI0713901A2 (pt) 2013-01-08
EP2066685A2 (en) 2009-06-10
AU2007263726A1 (en) 2008-01-03
DE602007012904D1 (de) 2011-04-14
CA2657973A1 (en) 2008-01-03
WO2008000743A2 (en) 2008-01-03
ATE500263T1 (de) 2011-03-15
ES2361886T3 (es) 2011-06-24
WO2008000743A3 (en) 2008-02-21
CN101479290A (zh) 2009-07-08
EP2066685B1 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
RU2009102512A (ru) Терапевтические соединения
CN101189234B (zh) Hcv的杂二环抑制剂
JP6323885B2 (ja) ヤヌスキナーゼ（ｊａｋ）阻害剤の硫酸水素塩およびその製造方法
RU2405783C2 (ru) Гетеробициклические ингибиторы вируса гепатита с (hcv)
CN116801884B (zh) 使用腺苷衍生物和衣壳抑制剂的针对hiv的组合疗法
JP2009541436A5 (https=)
RU2009102531A (ru) Терапевтические соединения
US10947225B2 (en) Phosphotidylinositol 3-kinase inhibitors
WO2016130271A1 (en) Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
JP2011520864A (ja) 置換キナゾリン
TWI638825B (zh) 抑制癌症及病毒之化合物
CN117241803A (zh) 嘌呤核苷、其中间体和其制备方法
RU2009102536A (ru) Терапевтические соединения
CN108794517B (zh) 一种精氨酸酶抑制剂及其制备方法与用途
JP2011520865A (ja) 置換キナゾリン
JPH05507267A (ja) カルボ―ヌクレオシド誘導体
JP2009541437A5 (https=)
CN111032629A (zh) 喹啉和萘啶的衍生物和组合物
JP5185823B2 (ja) がん治療用ジオキソラン誘導体
RU2837221C1 (ru) Новые производные пирролопиримидинов
RU2837216C1 (ru) Новые производные пирролопиримидинов
JP2023545414A (ja) Ｈｅｒ２の強力かつ選択的な阻害剤
RU2850268C1 (ru) Способ получения новых производных пирролопиримидинов
RU2837215C1 (ru) Новые производные пирролопиримидинов
RU2850227C1 (ru) Способ получения новых производных пирролопиримидинов

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20111004